Source - LSE Regulatory
RNS Number : 3701A
Advanced Oncotherapy PLC
29 September 2020

29 September 2020




("Advanced Oncotherapy" or the "Company")


Directorate Appointment


Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, today announces the appointment of Lori Cross as a Non-Executive Director of the Company with immediate effect.


Lori is a business executive with over 35 years of experience in building and transforming leading global organisations, specialising in Medical Technology and Life Sciences. Lori has successfully designed and commercialised numerous, disruptive healthcare business models, with executive positions at VIASYS Healthcare (acquired by Cardinal Health), Instrumentarium/GE Medical Systems, Smith & Nephew and Baxter Edwards Laboratories.


As President and Founder of MindSpan Consulting, Lori now consults with global clients on strategic innovation, operational scale-up/execution, and leadership development. Her clients have included Thermo Fisher Scientific, Medtronic, Nestle Healthcare, Danaher Beckman, GE Healthcare, and Novartis.


Lori is also currently a Non-Executive Board Director of Fastems and Electrosonic and a board adviser to TASC LLC. She has been teaching the Executive MBA Capstone Strategy program as an Adjunct Professor at the University of Wisconsin for over ten years. Lori was awarded a BS in Biomedical Engineering from Northwestern, an MBA from University of Phoenix and a Masters of Engineering - Biomedical Systems from Rensselaer Polytechnic Institute.


Dr Mike Sinclair, Executive Chairman of Advanced Oncotherapy, commented:


"On behalf of the Board, I am delighted to welcome Lori to Advanced Oncotherapy as a Non-Executive Director. Lori brings over 35 years of experience in commercialising disruptive MedTech innovations and her expertise will be invaluable to our business as we continue to progress the LIGHT system and develop commercial partnerships."


Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies 


The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Lori J. Cross (aged 60)


Full name: Lori Jo Cross

Former surname:  Zwirkoski (changed due to marriage)

Former forename: Laurie (changed due to spelling preference)



Current Directorships / Partnerships

Previous Directorships / Partnerships (last 5 years)

Electrosonic Ltd




Fastems OY AB


Mindspan Consulting LLC


AHLSTROM-MUNKSJÖ OYJ (formerly Ahlstrom Corporation)


Wall Family Enterprise INC


Neuromatrix LLC


M3 Insurance Solutions 


Demco Europe Limited


Timstar Laboratory Suppliers Limited


WF Education Group Holdings Limited


WF Education Group Limited


Maudesport Limited



* Ms Cross is considered a director of TASC LLC pursuant to the definition within the AIM Rules for Companies but this is not a statutory directorship position.


As of the date of this announcement, Lori J Cross holds no ordinary shares in the capital of the Company.


Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.


- ENDS -


Advanced Oncotherapy plc

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO

Allenby Capital Limited (Nomad and Joint Broker)

Nick Athanas / Liz Kirchner (Corporate Finance)

Amrit Nahal / Matt Butlin (Sales & Broking)

Tel: +44 (0) 20 3328 5656

SI Capital Ltd (Joint Broker)

Nick Emerson

Tel: +44 (0) 1483 413 500

Jon Levinson

Tel: +44 (0) 20 3871 4066

FTI Consulting (Financial PR & IR)

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000


Notes for Editors


About Advanced Oncotherapy Plc


Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.


Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.


Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.